Could BP plc, HSBC Holdings plc & GlaxoSmithKline plc Be Next To Cut Their Dividends?

Are the 5%+ yields from BP plc (LON:BP), HSBC Holdings plc (LON:HSBA) & GlaxoSmithKline plc (LON:GSK) too good to be true?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Income investors are feeling the squeeze as almost a fifth of all FTSE 100 companies have announced dividend cuts over the past year or so. Even companies which have previously been considered as safe and reliable investments, such as Tesco, Centrica and Severn Trent, were unable to maintain their dividend payouts after reporting sharp declines in earnings. And so far into 2016, 3 high profile dividend cuts have already been made, namely BHP Billiton, Rio Tinto and Barclays.

Here are 3 high yielding blue-chip stocks that could be next to cut their dividends:

Perilous

BP‘s (LSE: BP) earnings, which more than halved in 2015, are putting its 7.4% dividend yield in perilous territory. Underlying earnings covered just 80% of its dividend in 2015, but what’s worse is the company’s free cash flow position.

The company’s $18.6bn capex budget in 2015 was only just about covered by operating cash flow of $19.1bn, leaving an overwhelming majority of its $6.7bn dividend funded by new borrowings. The rapid growth in net debt, which rose 20% in 2015 alone and totalled $27.2 billion at the end of the year, demonstrates that with current oil prices, its existing dividend policy is unsustainable.

BP cannot afford to wait for oil prices to recover, and should act quickly to protect its balance sheet by cutting dividends soon. Oil prices do not seem to have much further to fall, but they are unlikely to bounce back any time soon. The shale revolution in North America has changed the dynamics of the energy market for good, and so the lower oil price environment appears to be the new normal.

BP’s dividend futures, which are exchange traded derivative contracts that allows investors to take positions on future dividend payments, are pricing in a 17% dividend cut in 2016, which indicates just a modest probability of a dividend cut this year. But for 2017, BP faces a bigger risk of a dividend cut, with a 40% dividend cut being priced in by the markets.

Risky

Over the past year, two UK banks – Standard Chartered and Barclays – have come to announce big dividend cuts, following weaker than expected earnings and increased restructuring costs. HSBC (LSE: HSBA), which has long been suffering from weak profitability, could be the next bank to cut its dividend.

Earnings per share (EPS) for the bank have fallen year-on-year for the past two consecutive years now, from $0.84 in 2013, to $0.65 in 2015,  whilst dividends per share have increased from $0.49 to $0.51 over the same period. This meant dividend cover has fallen from over 1.7x, to currently less than 1.3x.

HSBC’s dividend futures are pointing to a 10% and a 18% cut in its dividend in 2016 and 2017, respectively, which puts the bank at a substantially lower risk of dividend cuts. But, with uncertainties coming from slowing growth in emerging markets and a negative earnings trend, HSBC’s shares still appear to be a risky income investment.

Positive

GlaxoSmithKline (LSE: GSK) is the least cyclical of the three stocks mentioned here, which should also mean it is the safest. However, recent patent expirations for its major blockbuster drugs and intense competition from generic manufacturers have had a serious impact on revenues and earnings.

As a result of weak earnings, GSK has frozen its dividend at 80 pence per share for each year until 2018. But, despite the dividend freeze, GSK is unable to fully cover its dividend. A 15% drop in core EPS in 2015 caused its dividend cover to fall to just beneath the 1.0x mark in 2015.

Fortunately, for the drug company, the longer-term outlook is more positive. GSK benefits from an impressive pipeline of 40 new drugs, and already green shoots of recovery are becoming visible. New products accounted for £2 billion of sales in 2015, with signs of strong quarter-on-quarter growth rates. Looking forward, GSK expects £6 billion of sales will come from these new products by 2018, offsetting much of the impact of expiring blockbusters.

Jack Tang has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and HSBC Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

Down 32% and with a P/E of 9.5, is this FTSE 250 share too cheap to ignore?

This FTSE 250 share is in freefall after slashing guidance for this financial year. But Royston Wild eyes a potential…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Growth Shares

Why high oil prices could be good news for Lloyds shares

Jon Smith talks through the implications of elevated oil prices and translates that through to the potential impact on Lloyds'…

Read more »

Investing Articles

Lists of income stocks to buy almost never include this one — but with a forecast 8.2% yield, I think they should!

This FTSE firm, not always seen as an income play, has a forecast yield of 8.2%, underlining why it's one…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Aviva’s share price is down 13% to under £7, despite outstanding 2025 results! Time for me to buy more?

I think Aviva’s share price reflects an outdated view of the business, and that gap between perception and reality is…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Shell’s £33+ share price is near an all-time high, so why am I going to buy more as soon as possible?

Shell's strong cash generation and improving growth drivers contrast with a share price well below my valuation, suggesting major long‑term…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

An 8.4% forecast yield but down 16%! Time for me to buy more of this FTSE 100 passive income star?

This FTSE 100 passive‑income machine is delivering rising payouts and strong forecasts, and its share price suggests the market hasn’t…

Read more »

CEO Mark Zuckerberg at F8 2019 event
Investing Articles

£10,000 invested in Meta Platforms Stock 5 years ago is now worth…

Meta Platforms has been throwing good money after bad at Reality Labs since 2021, but the stock has more than…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

£7,500 invested in Diageo shares 5 weeks ago is now worth…

Our writer wonders if Diageo shares are worth a look at a 14-year low, or whether this FTSE 100 spirits…

Read more »